【摘要】 目的探讨血清白细胞介素6,8,18(IL-6,IL-8,IL-18)与肺癌的发生、发展、转移、疗效及预后的关系。方法采用双抗体夹心酶联免疫吸附试验(ELISA法)检测56例肺癌患者、18例肺结核患者治疗前后及40例健康人的血清IL-6,IL-8,IL-18含量,并进行比较分析。结果肺癌患者血清IL-6,IL-8,IL-18水平明显高于正常人和肺结核患者(P<0.01),且与临床分期及治疗效果有关(P<0.05或<0.01),与病理类型无关(P>0.05)。结论血清IL-6,IL-8,IL-18水平在一定程度上可反映肺癌发生、发展、转移情况及治疗效果,联合检测IL-6,IL-8,IL-18,对肺癌的诊断、治疗及预后评价有重要意义。更多还原

【Abstract】 Objective To study the relationships between serum interleukin-6, 8, 18 and the development, metastasis, curative effect and prognosis of lung cancer. Methods The serum interleukin-6, 8, 18 in 56 cases patients with lung cancer,18 cases patients with phthisis were determined by ELISA method before and after treatment, and 40 cases health people were control. Results The serum interleukin-6, 8, 18 level of patients with lung cancer was significantly higher than that in control groups and the patients with phthisis(P <0.01), and correlated with clinical stages and curative effect(P <0.05 or 0.01), Being foreign to pathology stages(P >0.05). Conclusion The serum interleukin-6, 8, 18 levels could reflected occurrence, development, metastasis and curative effect of the lung cancer in a certain extent, so it was importance for diagnosis, treatment and prognosis of lung cancer to combine examination IL-6, 8, 18.更多还原